Drug Intelligence Science (DIS®) Enhances Clinical Success from Target to Patient
HiFiBiO Therapeutics is pioneering curative immunotherapies for patients with high unmet medical needs. The company is targeting the root cause of disease through its unique Drug Intelligence Science (DIS®) platform. DIS® enables the deep understanding of cellular pathology across various diseases through proprietary single cell technology and AI/ML analytics. This platform is being deployed in target discovery, antibody selection, and predictive biomarker identification to achieve enhanced clinical success for patients.
